Intellia Therapeutics has paused dosing in its Phase 3 MAGNITUDE trials after a patient experienced severe liver toxicity, as ...

Intellia earlier this year reported a similar grade 4 liver enzyme elevation associated with the gene therapy nexiguran ...

Investing.com -- Intellia Therapeutics (NASDAQ:NTLA) stock fell 19% after the market close Wednesday after the U.S. Food and Drug Administration (FDA) placed a clinical hold on the company’s Phase 3 ...

Intellia Therapeutics (NASDAQ:NTLA) stock tumbled 50% Monday after the company announced it has temporarily paused patient dosing and screening for its Phase 3 clinical trials of nex-z due to a ...

USA-based Intellia Therapeutics has temporarily paused patient dosing and screening for its MAGNITUDE and MAGNITUDE-2 Phase ...

Conference call today at 8:30 a.m. ETCAMBRIDGE, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies ...

Recursion, Roche, and its Genentech subsidiary have unveiled a whole-genome map of specialized microglial immune cells that they plan to use toward revealing significant new targets in ...

Intellia Therapeutics (NASDAQ:NTLA) shares plummeted 50% on Monday after the company announced a temporary halt to patient ...

ELRIG Drug Discovery 2025 recognizes BubbleFect, a lipid-free cell delivery system that utilizes phase separation peptides ...

ANPELA is a software package to compare and assess the performance of different workflows for processing single-cell proteomic data, ensuring the user selects the most appropriate processing workflow ...